Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia | MicrobiomeTrials← Back to trialsNCT04746235
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2021-02-22Est. Completion: 2026-10-31
Enrollment target: 85 participants Locations- M D Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative NeoplasmAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia, Myelodysplasia-RelatedMyelodysplastic Syndrome
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific lab…
Birmingham, United StatesEst. completion May 15, 2029
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Acute Biphenotypic Leukemia
Acute Undifferentiated Leukemia
CLL (Chronic Lymphocytic Leukemia)
Chronic Myeloid Leukemia (CML)
MDS (Myelodysplastic Syndrome)
Non-Hodgkin Lymphomas
Hodgkins Lymphoma
Cutaneous T Cell Lymphomas (CTCL)
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marro…
Duarte, United StatesEst. completion Jul 14, 2026
Low-risk Myelodysplastic Syndromes
Phase I study with dose-escalation and expansion evaluating the safety and efficacy of oral Arsenic (ATO) in low-risk My…
Nice, FranceEst. completion Oct 24, 2026